| ACTH | Adrenocorticotropic Hormone |
| ASCO | American Society of Clinical Oncology |
| BPH | Benign Prostatic Hyperplasia |
| CRPC | Castration-Resistant Prostate Cancer |
| ECM | Extracellular Matrix |
| EMT | Epithelial–Mesenchymal Transition |
| MET | Mesennchymal–Epithelial-Transition |
| FACS | Fluorescence-activated cell sorting |
| FADD | Fas-Associated Death Domain |
| FAK | Focal Adhesion Kinase |
| FDA | Food and Drug Administration |
| HIF-α | Hypoxia-Inducible Factor-α |
| HTN | Hypertension |
| IGF | Insulin-Like Growth Factor |
| ILK | Integrin-Linked Kinase |
| PI3-K | Phosphatidylinositol 3-Kinase |
| RCC | Renal Cell Carcinoma |
| TCC | Transitional Cell Carcinoma (of the bladder) |
| TGF-β | Transforming Growth Factor-β |
| TKI | Tyrosine Kinase Inhibitors |
| TME | Tumor Microenvironment |
| TNF | Tumor Necrosis Factor |
| VHL | von Hippel-Lindau |
| VEGF | Vascular Endothelial Growth Factor |
| VEGFR | Vascular Endothelial Growth Factor Receptor |